2012
DOI: 10.1002/psb.915
|View full text |Cite
|
Sign up to set email alerts
|

Linagliptin: new DPP‐4 inhibitor for type 2 diabetes mellitus

Abstract: Linagliptin is a new DPP‐4 inhibitor licensed for use as monotherapy or in combination in type 2 diabetes. Our New products review presents the clinical data relating to its efficacy and adverse events and considers its place in treatment, particularly in patients with renal impairment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 14 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?